Samsara Bio Capital, LLC Viracta Therapeutics, Inc. Transaction History
Samsara Bio Capital, LLC
- $194 Million
- Q2 2024
A detailed history of Samsara Bio Capital, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 689,709 shares of VIRX stock, worth $151,735. This represents 0.19% of its overall portfolio holdings.
Number of Shares
689,709
Previous 689,709
-0.0%
Holding current value
$151,735
Previous $703,000
47.08%
% of portfolio
0.19%
Previous 0.22%
Shares
4 transactions
Others Institutions Holding VIRX
# of Institutions
45Shares Held
9.04MCall Options Held
10.9KPut Options Held
400-
Bvf Inc San Francisco, CA3.61MShares$795,2250.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$334,4520.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$255,4810.0% of portfolio
-
Laurion Capital Management LP New York, NY407KShares$89,6050.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$63,4850.07% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $8.26M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...